Efficacy and safety of the weight-loss drug rimonabant.
نویسندگان
چکیده
1 Quebec Heart Institute, Laval Hospital Research Center, Laval University, Sainte-Foy, Quebec G1V 4G5, Canada ; 2 Department of Diabetology, Metabolism, and Clinical Nutrition, University Hospital Antwerp, Faculty of Medicine (Department of Diabetology, Metabolism, and Clinical Nutrition), Edegem-Antwerp, Belgium ; 3 St Luke's-Roosevelt Hospital Center, New York, NY, USA; 4 Division of Diabetes, Nutrition, and Metabolic Disorders, CHU Sart Tilman, University of Liege, Liege, Belgium.
منابع مشابه
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
BACKGROUND Since the prevalence of obesity continues to increase, there is a demand for effective and safe anti-obesity agents that can produce and maintain weight loss and improve comorbidity. We did a meta-analysis of all published randomised controlled trials to assess the efficacy and safety of the newly approved anti-obesity agent rimonabant. METHODS We searched The Cochrane database and...
متن کاملAnti-obesity drugs: a review about their effects and their safety.
INTRODUCTION Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. AREAS COVERED The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy a...
متن کاملEfficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
OBJECTIVE To better define the efficacy and safety of rimonabant, the first selective cannabinoid type 1 (CB(1)) receptor antagonist, in a large population of overweight and obese patients using pooled efficacy data from three Phase III nondiabetes Rimonabant in Obesity and Related Metabolic Disorders (RIO) studies, selected efficacy data from the RIO-Diabetes study, and pooled safety data for ...
متن کاملSERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients
OBJECTIVE The purpose of this study was to assess the glucose-lowering efficacy and safety of rimonabant monotherapy in drug-naive type 2 diabetic patients. RESEARCH DESIGN AND METHODS The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients (SERENADE) was a 6-month, randomized, double-blind, placebo-controlled trial of 20 mg/day rimonabant in drug-naive patients with type 2 d...
متن کاملThe cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
The prevalence of obesity and associated metabolic/cardiovascular disease has reached epidemic proportions in industrialized and developing countries. Dietary and behavioural approaches are insufficient to maintain weight loss and to fight this trend. Therefore, effective and safe new pharmacological therapies are absolutely required to overcome this obesity burden. One promising new strategy i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Lancet
دوره 371 9612 شماره
صفحات -
تاریخ انتشار 2008